Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects

Update on the Use of Vonoprazan: A Competitive Acid Blocker

(2018) David Y. Graham et al.   GASTROENTEROLOGY

Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype

(2016) T. Kagami et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches

(2016) J Lee et al.   CTS-Clinical and Translational Science

Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease

(2016) Benjamin Lazarus et al.   JAMA Internal Medicine

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease

(2013) Michele Cicala   WORLD JOURNAL OF GASTROENTEROLOGY

Circulating microRNAs, potential biomarkers for drug-induced liver injury

(2009) K. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA